Mednet Logo
Community

What initial systemic approach will you recommend for metastatic pMMR HER2-positive esophageal/GEJ/gastric adenocarcinoma with PDL1 of 0?

Community PollStarted

What initial systemic approach will you recommend for metastatic pMMR HER2-positive esophageal/GEJ/gastric adenocarcinoma with PDL1 of 0?

18 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on

FOLFOX-trastuzumab-pembrolizumab is consistent with the 2023 Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline (Shah et al., PMID 36603169). In KEYNOTE-811, a response benefit was shown by adding pembrolizumab to trastuzumab plus chemotherapy. In this trial, 13%...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Henry Ford Cancer Institute (HFCI)
Answered on

FOLFOX or CAPOX plus trastuzumab.

Join for free or sign in to see the full answer